Clinical study of tumor supplies group of factors (TSGF) kit in detecting of carcinomas

Objective: To evaluate the clinical value of commercial tumor supplies group of factors (TSGF) kit for diagnosis of the malignant tumors. Methods:The serum levels of TSGF were assayed by spectrophotometry using commercial TSGF kit (Fujian Newland Bio. Co. China) in 1865 patients with carcinomas, which including more than 20 defferent kinds of tissue originally and 200 healthy controls.The serum TSGF levels were compared and analysed in clinical stages and clinipathological conditions. Results:At the bordline of 64U/ml and 71U/ml, the positive rates of TSGF were 53.0% and 26.8% for initiated tumors (n=527), 69.4% and 35.7% for non responders(n=98), 70 9% and 42.7% for recurrent and metastases (n=309), respectively.The serum TSGF levels were increased with the tumor progression. It was not found the TSGF levels correlated with ages and genders. At the level of 64U/ml, TSGF indicated new diagnosed tumors with a specificity of 98.0%, a sensitivity of 53.0%, a positive predictive value of 97.9%, and a negative predictive value of 43.9%. Moreover, the assay was able to detect distant metastasis and relapse with a specificity of 90.8%, a sensitivity of 70.9%, a positive predictive value of 80.5%, and a negative predictive value of 85.4%. Conclusions: The TSGF is a sensitive and specific as well as widely utility marker on diagnosis, monitoring response to treatment and prognosis of carcinomas. It is recommended that the clinical positive bordline of serum TSGF assay be 64U/ml, (64~71)U/ml be weakly positive, and over 71U/ml be strong positive.